

Advancing influenza virus treatment: in vitro and ex vivo studies of PI3K inhibitor-loaded lipid nanoparticles

Monday, September 14, 2026 1:44 PM (1 minute)

Influenza A viruses (IAVs) continue to pose a major global health threat. Annual vaccination provides only limited protection against emerging subtypes, and rising resistance to approved antivirals highlights the need for alternative therapeutic strategies. Host-directed therapies, such as targeting phosphatidylinositol 3-kinases (PI3Ks) exploited by IAVs during replication, offer promising alternatives. At the same time, advances in nanotechnology have established lipid nanoparticles (LNPs) as effective carriers that enhance drug stability, bioavailability, and targeted delivery. This study explores the combination of the PI3K inhibitor pictilisib with LNPs as a potential antiviral strategy. To improve circulation and distribution, LNPs commonly include “stealth” polymers. Here, established polyethylene glycol (PEG) Lipids were compared to poly(2 oxazoline) (POx) Lipids. PEG is widely used but associated with immunogenicity, whereas POx offers similar shielding with lower risk of hypersensitivity. Using both systems, pictilisib was efficiently encapsulated and retained antiviral and anti inflammatory activity comparable to the free drug in vitro. Notably, ex vivo experiments showed that POx-LNPs loaded with pictilisib were more effective than free pictilisib, indicating improved stability and local availability. These findings suggest that PI3K targeted LNP formulations may provide a promising approach for further development of future IAV intervention strategies.

Keywords

Professional status of the speaker

Postdoc

Junior scientist status

No, I am not a junior scientist.

Registration ID

53

Author: SCHROEDER, Josefine

Co-authors: Ms ISMAIL, Jana (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Jena, Germany); Ms HOLICK, Caroline T. (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Jena, Germany); Dr JUNGWIRTH, Johannes (Section of Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany); Ms KLEMENT, Laura (Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany); Dr HOEPPENER, Stephanie (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Jena, Germany); Dr KOSAN, Christian (Department of Biochemistry, Center for Molecular Biomedicine (CMB), Friedrich-Schiller-University Jena, Jena, Germany); Prof. SCHMIDTKE, Michaela (Section of Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany); Prof. LÖFFLER, Bettina (Institute of Medical Microbiology, Jena University Hospital, Jena, Germany); Dr WEBER, Christine (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Jena, Germany); Prof. SCHUBERT, Ulrich S. (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena,

Jena, Germany); Prof. HOFFMANN, Carsten (Institute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany); Dr SCHUBERT, Stephanie (Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Jena, Germany); Prof. EHRHARDT, Christina (Section of Experimental Virology, Institute of Medical Microbiology, Jena University Hospital, Jena, Germany)

Presenter: SCHROEDER, Josefine

Session Classification: Poster viewing

Track Classification: Antivirals and Vaccines